Cumberland Pharmaceuticals Inc (CPIX) — Analysis Summary
Cumberland Pharmaceuticals Inc (CPIX) has a market cap of $105.33M with year-over-year revenue growth of +17.6%. Net margin stands at -6.4%. The stock trades at a P/E ratio of -9.6.
Key Takeaways
- Revenue changed +17.6% year-over-year
- Net margin of -6.4%
- P/E ratio of -9.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CPIX posted revenue growth of +17.6% and trades at a P/E of -9.6.
Cumberland Pharmaceuticals Inc (CPIX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -42.2x — earnings do not cover interest payments
Current ratio at 0.96x — current liabilities exceed current assets
Operating margin at -23.6% — material operating losses
Net margin at -27.4% — significant losses
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
93
Headquarters
NASHVILLE,, TN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.